Table 1.
Clinical signs after single intravenous injection of muS110
| muS110 μg/kg | Hypomotility | Piloerection | Diarrhea | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0–4 h | 4–10 h | 10–24 h | 0–4 h | 4–10 h | 10 –24 h | 0–4 h | 4–10 h | 10–24 h | |
| 5 | ± | − | − | − | − | − | − | − | − |
| 15 | + | − | − | + | − | − | + | − | − |
| 50 | + | ± | − | + | ± | − | + | ± | − |
Female BALB/c mice (n = 20) received intravenous injection of 5, 15 or 50 μg/kg muS110. Clinical signs like piloerection, diarrhoea and hypomotility were monitored 1, 2, 4, 6, 8, 10 and 24 h after injection
− No effects, ± weak effects,+ moderate to strong effects